On September 22, HENGRUI PHARMA declined 3.04% in regular trading, trading at HK$48.0/share, with turnover of HK$60.72 million. The pullback follows a sharp rally of over 6% in the prior session, which was fueled by favorable analyst coverage from Citi and Bank of America, policy tailwinds from the national pharmaceutical industry development plan, and BlackRock's continued accumulation of H-shares to a 7.05% stake.

Despite the company announcing three new clinical trial approvals on the same day — HRS-1596 tablets for weight management and type 2 diabetes, HRS-4729 injection for chronic kidney disease (Phase II), and SHR-4595 injection for advanced solid tumors — the early-stage nature of these programs, with cumulative R&D investments of only RMB 18.4 million, RMB 87.6 million, and RMB 16.4 million respectively, appeared insufficient to sustain upward momentum. The broader Pharmaceuticals sector also traded lower, with SHANDONG XINHUA down 2.46%, SBP GROUP down 2.03%, HANSOH PHARMA down 1.63%, ASYMCHEM down 1.13%, and CSPC PHARMA down 0.78%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)